Extract to table

Penterra shall maintain a subject-injury sublimit of $10,000,000 per occurrence and $50,000,000 in the aggregate under the Briarcliff policy

Veridian and each participating Veridian Network site shall be named as additional insureds under the Briarcliff policy with respect to claims arising out of the CLARION trial

Penterra's position, which we maintained throughout the negotiation, was that Penterra must have the right to review all manuscripts, abstracts, presentations, and other publications arising from the CLARION trial prior to submission for publication

Prior to submitting any proposed manuscript, abstract, poster, presentation, or other publication (collectively, "Publication Materials") to any journal, conference, or other forum, the investigator shall submit the proposed Publication Materials to Penterra at least sixty (60) days prior to the planned submission date

During this sixty-day review period, Penterra shall have the right to review the Publication Materials for the presence of (a) confidential information belonging to Penterra, and (b) patentable subject matter

During this additional delay period, Penterra shall use commercially reasonable efforts to file any necessary patent applications